Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.70 |
| ▸ | ADRB2 | P07550 | 10/20 | 0.64 |
| ▸ | ADRB1 | P08588 | 10/20 | 0.64 |
| ▸ | ADRB3 | P13945 | 10/20 | 0.64 |
| ▸ | PRKCA | P17252 | 1/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.52 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.52 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | SLC1A5 | Q15758 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | F2 | P00734 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3391 | 1.00 | ALDH1A1 (0.70) | ALDH1A1ADRB2ADRB1ADRB3PRKCA | |
| SCHEMBL1866113 | 1.00 | ALDH1A1 (0.70) | ALDH1A1ADRB2ADRB1ADRB3PRKCA | |
| SCHEMBL20515564 | 0.98 | ALDH1A1 (0.68) | ALDH1A1ADRB2ADRB1ADRB3PRKCA | |
| Benzoic Acid SCHEMBL136510 | 0.95 | ALDH1A1 (0.64) | ALDH1A1ADRB2ADRB1ADRB3PRKCA | |
| Benzoic Acid SCHEMBL7688676 | 0.95 | ALDH1A1 (0.64) | ALDH1A1ADRB2ADRB1ADRB3PRKCA | |
| Benzoic Acid SCHEMBL28388934 | 0.95 | ALDH1A1 (0.64) | ALDH1A1ADRB2ADRB1ADRB3PRKCA | |
| Benzoic Acid SCHEMBL9956241 | 0.95 | ALDH1A1 (0.64) | ALDH1A1ADRB2ADRB1ADRB3PRKCA | |
| Acetic Acid SCHEMBL28698833 | 0.95 | ALDH1A1 (0.64) | ALDH1A1ADRB2ADRB1ADRB3PRKCA | |
| SCHEMBL7144537 | 0.91 | ALDH1A1 (0.64) | ALDH1A1ADRB2ADRB1ADRB3PRKCA | |
| SCHEMBL295042 | 0.90 | ALDH1A1 (0.78) | ALDH1A1ADRB2ADRB1ADRB3PRKCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220259226-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | ABBVIE INC (US) | 2022-08-18 | — | — | US | disclosed |
| EP-3197460-B1 | DERMOCOSMETIC OR PHARMACEUTICAL USE OF A COMPOSITION CONTAINING AT LEAST ONE INHIBITOR OF CERTAIN CHEMOKINES | GREENPHARMA SAS (FR) | 2022-04-20 | — | — | EP | disclosed |
| US-20210292339-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | ABBVIE INC (US) | 2021-09-23 | — | — | US | disclosed |
| US-20200255451-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | ABBVIE INC (US) | 2020-08-13 | — | — | US | disclosed |
| EP-3668503-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | AbbVie Inc. (US) | 2020-06-24 | — | — | EP | disclosed |
| EP-3668504-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | AbbVie Inc. (US) | 2020-06-24 | — | — | EP | disclosed |
| WO-2019035899-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | ABBVIE INC. (US) | 2019-02-21 | — | — | WO | disclosed |
| WO-2019035914-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | ABBVIE INC. (US) | 2019-02-21 | — | — | WO | disclosed |
| US-20190055264-A1 | Macrocyclic MCL-1 inhibitors and methods of use | AbbVie Deutschland GmbH & Co. KG (DE) | 2019-02-21 | — | — | US | disclosed |
| US-20180118708-A1 | CYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-05-03 | — | — | US | disclosed |
| EP-3296296-A1 | CYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2018-03-21 | — | — | EP | disclosed |
| US-20170281653-A1 | DERMOCOSMETIC OR PHARMACEUTICAL USE OF A COMPOSITION CONTAINING AT LEAST ONE INHIBITOR OF CERTAIN CHEMOKINES | GREENPHARMA SAS (FR) | 2017-10-05 | — | — | US | disclosed |
| US-20170281653-A1 | DERMOCOSMETIC OR PHARMACEUTICAL USE OF A COMPOSITION CONTAINING AT LEAST ONE INHIBITOR OF CERTAIN CHEMOKINES | GREENPHARMA SAS (FR) | 2017-10-05 | — | — | US | disclosed |
| EP-1935879-B1 | SUBSTITUTED CYCLOALKENE DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2016-05-11 | — | — | EP | disclosed |
| WO-2016046456-A1 | DERMOCOSMETIC OR PHARMACEUTICAL USE OF A COMPOSITION CONTAINING AT LEAST ONE INHIBITOR OF CERTAIN CHEMOKINES | GREENPHARMA (FR) | 2016-03-31 | — | — | WO | disclosed |
| US-RE43858-E1 | Substituted cycloalkene derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-12-11 | — | — | US | disclosed |
| US-7935835-B2 | Substituted cycloalkene derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-05-03 | — | — | US | disclosed |
| US-20090233952-A1 | SUBSTITUTED CYCLOALKENE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-09-17 | — | — | US | disclosed |
| EP-1935879-A1 | SUBSTITUTED CYCLOALKENE DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2008-06-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210292339-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | MCL1, BCL2A1, BCL2L10 | ALDH1A1 647/4885ADRB2 4332/4885ADRB1 3562/4885 |
| US-20170281653-A1 | DERMOCOSMETIC OR PHARMACEUTICAL USE OF A COMPOSITION CONTAINING AT LEAST ONE INHIBITOR OF CERTAIN CHEMOKINES | CCL2, CCL11, CCL5 | ALDH1A1 1163/4885ADRB2 2720/4885ADRB1 2665/4885 |
| US-20180118708-A1 | CYCLIC COMPOUND | TLR4, TLR3, TLR9 | ALDH1A1 973/4885ADRB2 3375/4885ADRB1 2429/4885 |
| US-20190055264-A1 | Macrocyclic MCL-1 inhibitors and methods of use | MCL1, BCL2A1, BCL2L10 | ALDH1A1 647/4885ADRB2 4332/4885ADRB1 3562/4885 |
| US-20090233952-A1 | SUBSTITUTED CYCLOALKENE DERIVATIVE | CD40, LITAF, TNF | ALDH1A1 4252/4885ADRB2 367/4885ADRB1 226/4885 |
| US-20200255451-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | MCL1, BCL2A1, BCL2L10 | ALDH1A1 647/4885ADRB2 4332/4885ADRB1 3562/4885 |
| US-20220259226-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | MCL1, BCL2A1, BCL2L10 | ALDH1A1 647/4885ADRB2 4332/4885ADRB1 3562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.